[Vascular dementia].
Vascular dementia (VaD) constitutes the second most frequent cause of dementia following Alzheimer's disease (AD). In contrast to AD, VaD encompasses a variety of conditions and dementia mechanisms including multiple and strategic infarcts, widespread white matter lesions and hemorrhages. The diagnosis of VaD is based on the patient history, the clinical evaluation and neuroimaging. Treatment of VaD should account for the underlying vascular condition and is directed towards the control of vascular risk factors and stroke prevention. The need for early diagnosis and preventive treatment has promoted the concept of vascular cognitive impairment (VCI). Harmonization standards for the description and study of VCI have recently been published. A common and distinct subtype of VaD is subcortical ischemic vascular dementia (SIVD) which is related to cerebral small vessel disease. SIVD is clinically characterized by impairment of executive functions and processing speed with relatively preserved memory. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a genetic variant of SIVD, represents an important differential diagnosis and may serve as a model of SIVD.
Peters
N
N
Neurologische Klinik und Poliklinik, Klinikum Großhadern, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377, München, Deutschland. Nils.Peters@med.uni-muenchen.de
Dichgans
M
M
D000368:Aged; D001921:Brain / Q000473:pathology; D046589:CADASIL / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D015161:Dementia, Multi-Infarct / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D015140:Dementia, Vascular / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D003937:Diagnosis, Differential; D006801:Humans; D033183:Interdisciplinary Communication; D018810:Magnetic Resonance Angiography; D008279:Magnetic Resonance Imaging; D008559:Memantine / Q000627:therapeutic use; D009483:Neuropsychological Tests; D010348:Patient Care Team; D011157:Population Dynamics; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D020521:Stroke / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy
D002800:Cholinesterase Inhibitors; D008559:Memantine
Stroke. 2004 Jul;35(7):1603-8
15155961
Brain. 2004 Nov;127(Pt 11):2533-9
15364702
Lancet Neurol. 2003 Feb;2(2):89-98
12849265
Stroke. 2006 Sep;37(9):2220-41
16917086
Lancet Neurol. 2009 Nov;8(11):1006-18
19782001
Neurology. 1993 Feb;43(2):250-60
8094895
Lancet. 1998 Oct 24;352(9137):1347-51
9802273
Acta Psychiatr Scand. 2009 Apr;119(4):252-65
19236314
Am J Psychiatry. 2005 Nov;162(11):2078-85
16263847
Arch Intern Med. 2003 May 12;163(9):1069-75
12742805
Neurology. 1998 Aug;51(2):452-7
9710018
Lancet Neurol. 2007 Sep;6(9):782-92
17689146
Lancet Neurol. 2008 Apr;7(4):310-8
18296124
JAMA. 1997 Mar 12;277(10):813-7
9052711
J Am Geriatr Soc. 2008 Aug;56(8):1424-33
18662209
JAMA. 2005 Oct 19;294(15):1934-43
16234500
Neurology. 2001 Mar 13;56(5):628-34
11245715
Curr Atheroscler Rep. 2007 Oct;9(4):326-32
18173961
Br J Psychiatry. 2002 Mar;180:270-6
11872521
Neurology. 1998 Jul;51(1):159-62
9674796
Stroke. 2005 Dec;36(12):2559-65
16269644
Neuroepidemiology. 2003 May-Jun;22(3):161-4
12739527
Neuroepidemiology. 1995;14(5):240-57
7477666
Neurology. 2006 May 23;66(10):1517-22
16717211
Lancet Neurol. 2002 Nov;1(7):426-36
12849365
Neurobiol Aging. 2006 Dec;27(12):1769-85
16300856
Ann Neurol. 1998 Nov;44(5):731-9
9818928